Research programme: personalised orphan disease therapeutics - Perlara

Drug Profile

Research programme: personalised orphan disease therapeutics - Perlara

Alternative Names: Batten disease therapeutic - Perlara; Leigh syndrome therapeutic - Perlara; NGLY1 therapeutic - Perlara; NPC1 therapeutic - Perlara; PERL 101

Latest Information Update: 21 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Perlstein Lab
  • Developer Perlara
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Niemann-Pick disease type C

Highest Development Phases

  • Preclinical Niemann-Pick disease type C
  • Research Inborn genetic disorders; Leigh disease; Neuronal ceroid lipofuscinosis

Most Recent Events

  • 20 Oct 2016 Perlara collaborates with Novartis for the development of drugs for lysosomal storage disorders including Niemann-Pick Type C disease
  • 20 Jan 2016 Early research in Inborn genetic disorders in USA (unspecified route)
  • 20 Jan 2016 Early research in Leigh disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top